Abbott Laboratories

New York Stock Exchange
Back to all articles
Bullish +75

Intuitive Surgical Upgraded to Buy by Citi — Plus Key Moves on Stryker and Abbott

AI-generated analysis

📈 Citi upgraded Intuitive Surgical (ISRG) from Neutral to Buy while opening a 90-day catalyst watch on Stryker (SYK).

📉 Analyst Joanne Wuensch maintained a Buy rating for Abbott (ABT) but trimmed its price target by $4 following Q4 earnings.

💊 The firm argues that U.S. medical technology fundamentals remain healthy and intact despite recent broad market volatility and sector pullbacks.

🤖 Intuitive Surgical delivered strong Q4 2025 results with revenue of $2.87 billion (up 18.76%) and non-GAAP EPS of $2.53 versus the $2.26 estimate.

🔭 The da Vinci 5 robotic platform continues its multi-year adoption cycle, placing 303 systems in Q4 alone to reach a total installed base of 11,106.

🦾 Stryker crossed a significant milestone by surpassing $25 billion in annual revenue for the first time, reaching full-year revenue of $25.12 billion up 11.16%.

⚠️ Citi added a catalyst watch to Stryker due to potential near-term inflection points from early data on the Mako RPS handheld robotic system.

🏥 Abbott reported modest Q4 revenue growth of 4.42% with its medical devices segment providing clear signals, including $2.0 billion in CGM sales up 15%.

🤝 The price target cut for Abbott reflects the more modest growth profile of a diversified healthcare giant rather than any structural concerns about the company.

💰 Stryker's adjusted operating margins expanded at least 100 basis points for the second consecutive year, strengthening its financial foundation.

🔮 Intuitive Surgical's Q4 placement of 303 da Vinci systems was more than double the 174 units placed in the same quarter a year prior.

📉 Abbott's shares are down 18% over the past year while facing significant pressure from its pending $21 billion acquisition of Exact Sciences.

⚖️ Intuitive Surgical trades at a premium valuation of roughly 49x forward earnings, reflecting its strong competitive moat in robotic-assisted surgery.

🛡️ Citi suggests that Intuitive has been unduly caught in the market downdraft without any deterioration in the underlying business fundamentals.

🌐 The broader stock market fear, indicated by the VIX surging to 25.50, has compressed valuations indiscriminately across the MedTech sector.

Bullish Signals
  • Intuitive Surgical was upgraded to a Buy rating by Citi, signaling strong investor confidence despite recent market volatility.
  • Intuitive delivered exceptional performance in Q4 2025 with revenue of $2.87 billion up 18.76% year-over-year and non-GAAP EPS of $2.53 versus a consensus estimate of $2.26.
  • The da Vinci 5 platform adoption is accelerating, placing 303 systems in Q4 alone compared to 174 a year earlier, with the total installed base growing 12% to reach 11,106 systems.
  • Stryker crossed a significant milestone by surpassing $25 billion in annual revenue for the first time, achieving full-year revenue of $25.12 billion up 11.16%.
  • Stryker has demonstrated consistent double-digit revenue and earnings growth as the foundation for its Buy rating, with adjusted operating margins expanding at least 100 basis points for the second consecutive year.
  • Abbott's medical devices segment provided a clear growth signal with CGM sales up 15% to reach $2.0 billion in Q4.
  • Abbott is positioned for long-term transformation via its pending $21 billion acquisition of Exact Sciences, expected to close in Q2 2026, which adds a cancer diagnostics dimension.
  • Intuitive Surgical trades at roughly 49x forward earnings with management guidance calling for da Vinci procedure growth of 13% to 15% in 2026.
  • Stryker offers meaningful upside to analyst targets with a forward P/E of roughly 24x and the broader analyst consensus price target sitting at $424.89.
  • Abbott maintains a solid valuation case for income-oriented investors with a forward P/E near 20x and an impressive 54-year dividend growth streak.
Risk Factors
  • The stock is trading around $485.85, down 14.2% year-to-date after closing 2025 near a 52-week high of $603.88, indicating significant price suppression despite strong fundamentals.
  • Citi trimmed its price target on Abbott by $4 to reflect the more modest growth profile typical of a diversified healthcare giant rather than addressing any immediate structural risks.
  • Abbott shares are down 18% over the past year and posted only a modest 4.42% year-over-year revenue gain in Q4, trailing peers in growth performance.
  • The VIX has surged to 25.50, sitting at the 92.6th percentile of its 12-month range, suggesting broad-market fear is compressing valuations indiscriminately and dragging down strong names like Intuitive Surgical without fundamental justification.
  • Intuitive Surgical faces a tariff headwind of approximately 1.2% of revenue already baked into management's outlook for the next year, which could suppress top-line growth.
  • The company's 2026 guidance anticipates da Vinci procedure growth deceleration to 13%-15%, down from double-digit speeds in previous years, signaling a potential slowdown in adoption momentum.
Full Analysis
Citi upgraded Intuitive Surgical (ISRG) to a Buy rating from Neutral while maintaining its Buy ratings on Stryker (SYK) and Abbott Laboratories (ABT), citing healthy fundamentals for the medical technology sector despite recent market volatility. The firm, led by analyst Joanne Wuensch, argues that Intuitive Surgical's sell-off has been driven by broader macro fear rather than any deterioration in the business, particularly noting the double-digit growth trajectory continues with the da Vinci 5 platform in its early adoption cycle. Specifically, Citi cut the price target on Abbott by $4 to reflect the more modest growth profile of a diversified healthcare giant following Q4 reports, while adding a 90-day catalyst watch to Stryker to monitor data from its Mako RPS handheld robotic system set for limited release in 2026. Intuitive Surgical is the primary focus of the upgrade, with Citi highlighting that the company delivered one of its strongest years recently despite trading sharply off its highs. In Q4 2025, ISRG posted revenue of $2.87 billion, an 18.76% year-over-year increase, and non-GAAP EPS of $2.53 against a consensus of $2.26. The da Vinci 5 system saw significant momentum with 303 units placed in Q4 alone, bringing the total installed base to 11,106 systems, up 12%. Citi maintains a price target of $590 for ISRG, implying upside from its current trading level of approximately $485.85, even though the stock trades at a premium forward P/E of roughly 49x reflecting its competitive moat in robotic surgery. Stryker is noted for crossing the $25 billion annual revenue mark in 2025 with full-year revenue of $25.12 billion, up 11.16%, and adjusted operating margins expanding at least 100 basis points for the second consecutive year. Currently trading around $358.65, Stryker's Citi price target is $420, with a forward P/E of roughly 24x that reflects its mature and diversified business mix compared to Intuitive. Abbott Laboratories is highlighted for its pending $21 billion acquisition of Exact Sciences expected to close in Q2 2026, which adds cancer diagnostics to its portfolio, while its medical devices segment continues to grow with CGM sales up 15% to $2.0 billion despite overall revenue growth moderating to 4.42% in Q4. The broader market context shows the VIX surged to 25.50 as of early March, sitting at the 92.6th percentile of its 12-month range, indicating significant fear that has compressed valuations indiscriminately across the sector. Citi believes this macro backdrop is responsible for the price action rather than a lack of operational momentum, particularly for Intuitive Surgical which was trading down 14.2% year-to-date after closing near a 52-week high in late 2025. The consensus analyst price target for Intuitive is even higher at $609.82, suggesting that the current market price may not fully reflect the long-term potential of the company's robotic-assisted surgery growth and earnings leverage capabilities.